• Richard A. Hubner


In the developed world mortality from major chronic diseases such as cardiovascular and cerebrovascular disease has decreased substantially in the past half century, whilst cancer mortality has only recently shown a modest decline [1]. Despite novel chemotherapeutic and biological agents for cancer treatment, prognosis for the large majority of patients diagnosed with advanced cancer remains poor, and cancer is now the most frequent cause of death in men and women under 85 years in the United States [2]. A promising alternative approach is to prevent the development of invasive disease by treating carcinogenesis rather than cancer itself. Cancer chemoprevention is classically defined as the use of natural, synthetic, or biological chemical agents to interfere with the process of carcinogenesis by either preventing the development of a pre-invasive lesion, inhibiting the progression of a pre-invasive lesion into an invasive cancer, or causing a reversal of a pre-invasive lesion towards the normal state [3]. Although there is a large body of pre-clinical data supporting the concept of cancer chemoprevention, a relatively small number of clinical chemoprevention trials have reported significant benefits, and the use of chemopreventive agents in routine clinical practice is currently limited to hig­h-risk cancer predisposition syndromes.


Chemopreventive Agent Cancer Chemoprevention Breast Cancer Risk Reduction Chemoprevention Trial Regular Aspirin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Ford ES, Ajani UA, Croft JB et al (2007) Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med 356:2388–2398PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66PubMedCrossRefGoogle Scholar
  3. 3.
    Sporn MB, Dunlop NM, Newton DL et al (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332–1338PubMedGoogle Scholar
  4. 4.
    World Cancer Research Fund/American Institute for Cancer Research: Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington DC, 2007Google Scholar
  5. 5.
    Atkin WS, Morson BC, Cuzick J (1992) Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 326:658–662PubMedCrossRefGoogle Scholar
  6. 6.
    Winawer SJ, Zauber AG, Ho MN et al (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329:1977–1981PubMedCrossRefGoogle Scholar
  7. 7.
    Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6:963–968PubMedCrossRefGoogle Scholar
  8. 8.
    Freedman AN, Seminara D, Gail MH et al (2005) Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 97:715–723PubMedCrossRefGoogle Scholar
  9. 9.
    Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886PubMedCrossRefGoogle Scholar
  10. 10.
    Costantino JP, Gail MH, Pee D et al (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541–1548PubMedCrossRefGoogle Scholar
  11. 11.
    Song J, Sohn KJ, Medline A et al (2000) Chemopreventive effects of dietary folate on intestinal polyps in Apc+/−Msh2−/− mice. Cancer Res 60:3191–3199PubMedGoogle Scholar
  12. 12.
    Song J, Medline A, Mason JB et al (2000) Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse. Cancer Res 60:5434–5440PubMedGoogle Scholar
  13. 13.
    Baxter NN, Goldwasser MA, Paszat LF et al (2009) Association of colonoscopy and death from colorectal cancer. Ann Intern Med 150:1–8PubMedGoogle Scholar
  14. 14.
    Labianca R, Beretta GD, Mosconi S et al (2005) Colorectal cancer: screening. Ann Oncol 16(Suppl 2):ii127–ii132PubMedCrossRefGoogle Scholar
  15. 15.
    Goodman GE (2008) Assessing toxicity in cancer chemoprevention trials: the other side of the coin. Cancer Prev Res (Phila Pa) 1:499–502CrossRefGoogle Scholar
  16. 16.
    The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029–1035CrossRefGoogle Scholar
  17. 17.
    Omenn GS, Goodman GE, Thornquist MD et al (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334: 1150–1155PubMedCrossRefGoogle Scholar
  18. 18.
    Bjelakovic G, Nikolova D, Gluud LL et al (2007) Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297:842–857PubMedCrossRefGoogle Scholar
  19. 19.
    Cole BF, Baron JA, Sandler RS et al (2007) Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297:2351–2359PubMedCrossRefGoogle Scholar
  20. 20.
    Solomon SD, McMurray JJ, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080PubMedCrossRefGoogle Scholar
  21. 21.
    Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388PubMedCrossRefGoogle Scholar
  22. 22.
    Kune GA, Kune S, Watson LF (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48:4399–4404PubMedGoogle Scholar
  23. 23.
    Hong WK, Lippman SM, Itri LM et al (1990) Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795–801PubMedCrossRefGoogle Scholar
  24. 24.
    Lippman SM, Klein EA, Goodman PJ et al (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301:39–51PubMedCrossRefGoogle Scholar
  25. 25.
    Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652–1662PubMedCrossRefGoogle Scholar
  26. 26.
    Cuzick J, Powles T, Veronesi U et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300PubMedCrossRefGoogle Scholar
  27. 27.
    Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727–2741PubMedCrossRefGoogle Scholar
  28. 28.
    Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 281:2189–2197PubMedCrossRefGoogle Scholar
  29. 29.
    Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137PubMedCrossRefGoogle Scholar
  30. 30.
    Thompson IM, Goodman PJ, Tangen CM et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224PubMedCrossRefGoogle Scholar
  31. 31.
    Goodman PJ, Thompson IM Jr, Tangen CM et al (2006) The prostate cancer prevention trial: design, biases and interpretation of study results. J Urol 175:2234–2242PubMedCrossRefGoogle Scholar
  32. 32.
    Unger JM, Thompson IM Jr, LeBlanc M et al (2005) Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer 103:1375–1380PubMedCrossRefGoogle Scholar
  33. 33.
    Brown JR, DuBois RN (2005) COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23:2840–2855PubMedCrossRefGoogle Scholar
  34. 34.
    Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252–266PubMedCrossRefGoogle Scholar
  35. 35.
    Mamdani M, Rochon PA, Juurlink DN et al (2002) Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 325:624PubMedCrossRefGoogle Scholar
  36. 36.
    Chan TA (2002) Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 3:166–174PubMedCrossRefGoogle Scholar
  37. 37.
    Paganini-Hill A, Chao A, Ross RK et al (1989) Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 299:1247–1250PubMedCrossRefGoogle Scholar
  38. 38.
    Garcia-Rodriguez LA, Huerta-Alvarez C (2001) Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 12:88–93PubMedCrossRefGoogle Scholar
  39. 39.
    Chan AT, Giovannucci EL, Meyerhardt JA et al (2005) Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294:914–923PubMedCrossRefGoogle Scholar
  40. 40.
    Steinbach G, Lynch PM, Phillips RK et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952PubMedCrossRefGoogle Scholar
  41. 41.
    Gann PH, Manson JE, Glynn RJ et al (1993) Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85:1220–1224PubMedCrossRefGoogle Scholar
  42. 42.
    Cook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294:47–55PubMedCrossRefGoogle Scholar
  43. 43.
    Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369:1603–1613PubMedCrossRefGoogle Scholar
  44. 44.
    Baron JA, Cole BF, Sandler RS et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891–899PubMedCrossRefGoogle Scholar
  45. 45.
    Benamouzig R, Deyra J, Martin A et al (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125:328–336PubMedCrossRefGoogle Scholar
  46. 46.
    Sandler RS, Halabi S, Baron JA et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883–890PubMedCrossRefGoogle Scholar
  47. 47.
    Logan RFA, Muir KR, Grainge MJ, on behalf of the UKCAP Trial Group et al (2006) Aspirin for the prevention of recurrent colorectal adenomas – results of the UKCAP trial. Gut 55(Suppl 2):A90Google Scholar
  48. 48.
    Cole BF, Logan RF, Halabi S et al (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101:256–266PubMedCrossRefGoogle Scholar
  49. 49.
    Bresalier RS, Sandler RS, Quan H et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–1102PubMedCrossRefGoogle Scholar
  50. 50.
    Solomon SD, Wittes J, Finn PV et al (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117:2104–2113PubMedCrossRefGoogle Scholar
  51. 51.
    Das D, Chilton AP, Jankowski JA (2009) Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res 181:161–169PubMedCrossRefGoogle Scholar
  52. 52.
    Meyskens FL Jr, McLaren CE, Pelot D, et al. (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila Pa) 1:32–38CrossRefGoogle Scholar
  53. 53.
    Babbar N, Ignatenko NA, Casero RA Jr et al (2003) Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem 278:47762–47775PubMedCrossRefGoogle Scholar
  54. 54.
    Rao CV, Tokumo K, Rigotty J et al (1991) Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 51: 4528–4534PubMedGoogle Scholar
  55. 55.
    Piazza GA, Alberts DS, Hixson LJ et al (1997) Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57:2909–2915PubMedGoogle Scholar
  56. 56.
    Meyskens FL Jr, Emerson SS, Pelot D et al (1994) Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst 86:1122–1130PubMedCrossRefGoogle Scholar
  57. 57.
    Walther A, Johnstone E, Swanton C et al (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9:489–499PubMedCrossRefGoogle Scholar
  58. 58.
    Eberhart CE, Coffey RJ, Radhika A et al (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183–1188PubMedGoogle Scholar
  59. 59.
    Castells A, Paya A, Alenda C et al (2006) Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency. Clin Cancer Res 12:1686–1692PubMedCrossRefGoogle Scholar
  60. 60.
    McLean MH, Murray GI, Fyfe N et al (2008) COX-2 expression in sporadic colorectal adenomatous polyps is linked to adenoma characteristics. Histopathology 52:806–815PubMedCrossRefGoogle Scholar
  61. 61.
    Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131–2142PubMedCrossRefGoogle Scholar
  62. 62.
    Chan AT, Ogino S, Fuchs CS (2009) Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302:649–658PubMedCrossRefGoogle Scholar
  63. 63.
    Haile RW, Yochim JM, Cortessis VK et al (2005) A molecular/epidemiologic analysis of expression of cyclooxygenases 1 and 2, use of nonsteroidal antiinflammatory drugs, and risk of colorectal adenoma. Clin Colorectal Cancer 4:390–395PubMedCrossRefGoogle Scholar
  64. 64.
    Fuchs CS, Meyerhardt JA, Heseltine DL et al (2005) Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. J Clin Oncol 23:3530Google Scholar
  65. 65.
    Houlston RS, Webb E, Broderick P et al (2008) Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet 40:1426–1435PubMedCrossRefGoogle Scholar
  66. 66.
    Martinez ME, O’Brien TG, Fultz KE et al (2003) Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci U S A 100:7859–7864PubMedCrossRefGoogle Scholar
  67. 67.
    Hubner RA, Muir KR, Liu JF et al (2008) Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. Clin Cancer Res 14:2303–2309PubMedCrossRefGoogle Scholar
  68. 68.
    Barry EL, Baron JA, Bhat S et al (2006) Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. J Natl Cancer Inst 98:1494–1500PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of MedicineRoyal Marsden HospitalLondonUK

Personalised recommendations